Comparison of the Efficacy between Tirofiban Combined with Argatroban and Tirofiban in the Treatment of Acute Branch Atheromatous Disease

doi:10.3969/j.issn.1673-5765.2025.06.012

Abstract

Abstract: Objective To explore the effect of tirofiban combined with argatroban in the treatment of acute branch atheromatous disease (BAD).
Methods Patients with mild BAD treated at the Yancheng Third People’s Hospital from January 2022 to May 2024 were retrospectively included. According to the treatment plan, patients were divided into the tirofiban combined with argatroban group (dual-pump group) and the tirofiban group. Early neurological deterioration (END) was defined as an increase in NIHSS score of≥2 points or an increase in motor function score of≥1 point within 7 days of onset. A good prognosis was defined as a mRS score of＜2 at 3 months after onset.
Results A total of 83 patients with mild BAD were included, with 31 patients in the dual-pump group and 52 patients in the tirofiban group. The baseline clinical data between the two groups showed no statistically significant difference. The proportion of END occurrence in the dual-pump group was statistically lower than that in the tirofiban group [6.5% (2/31) vs. 26.9% (14/52), P=0.046]. The proportion of good prognosis patients in the dual-pump group was statistically higher than that in the tirofiban group [96.8% (30/31) vs. 76.9% (40/52), P=0.036]. In the dual-pump group, one patient developed oral mucosal bleeding, while no intracranial hemorrhage events occurred in all patients. Multivariate logistic regression showed that tirofiban combined with argatroban was the treatment of BAD independent influencing factors for non-END and good prognosis (P<0.05).
Conclusions The combination of tirofiban and argatroban in treating mild BAD patients can reduce the incidence of END, increase the proportion of patients with good prognosis at 3 months after onset, and does not increase the risk of intracranial hemorrhage.

Key words: Acute branch atheromatous disease; Early neurological deterioration; Tirofiban combined with argatroban

摘要： 目的初步探索替罗非班联合阿加曲班治疗急性穿支动脉粥样硬化性脑梗死（branch atheromatous disease，BAD）的效果。
方法回顾性纳入2022年1月—2024年5月在盐城市第三人民医院诊治的轻型BAD患者。根据治疗方案，将患者分为替罗非班联合阿加曲班组（双泵组）和替罗非班组。发病7 d内NIHSS评分增加≥2分或肢体功能评分增加≥1分定义为早期神经功能恶化（early neurological deterioration，END），发病3个月mRS评分＜2分定义为预后良好。
结果共纳入轻型BAD患者83例，其中双泵组31例，替罗非班组52例，两组基线指标比较差异无统计学意义。双泵组发生END的比例低于替罗非班组［6.5%（2/31）vs. 26.9%（14/52），P=0.046］，差异有统计学意义。双泵组预后良好比例高于替罗非班组［96.8%（30/31）vs. 76.9%（40/52），P=0.036］，差异有统计学意义。双泵组有1例患者出现口腔黏膜渗血，所有患者均未发生颅内出血事件。多因素logistic回归分析结果显示，替罗非班联合阿加曲班治疗是BAD患者不发生END和预后良好的独立影响因素（P＜0.05）。
结论替罗非班联合阿加曲班治疗较替罗非班治疗能够降低轻型BAD患者END的发生率，增加发病3个月预后良好的比例，且不增加颅内出血风险。

关键词: 急性穿支动脉粥样硬化性脑梗死; 早期神经功能恶化; 替罗非班联合阿加曲班

CLC Number:

LUO Rong, SHI Haicun. Comparison of the Efficacy between Tirofiban Combined with Argatroban and Tirofiban in the Treatment of Acute Branch Atheromatous Disease[J]. Chinese Journal of Stroke, 2025, 20(6): 762-768.

罗容, 侍海存. 替罗非班联合阿加曲班对比替罗非班治疗急性穿支动脉粥样硬化性脑梗死的效果观察[J]. 中国卒中杂志, 2025, 20(6): 762-768.

References

[1] YAMAMOTO Y，OHARA T，HAMANAKA M，et al. Characteristics of intracranial branch atheromatous disease and its association with progressive motor deficits[J]. J Neurol Sci，2011，304（1/2）：78-82.
[2] MEN X J，LI J J，ZHANG B J，et al. Homocysteine and C-reactive protein associated with progression and prognosis of intracranial branch atheromatous disease[J/OL]. PLoS One，2013，8（9）：e73030[2025-01-10]. https://doi.org/10.1371/journal.pone.0073030.
[3] PETRONE L，NANNONI S，DEL BENE A，et al. Branch atheromatous disease：a clinically meaningful，yet unproven concept[J]. Cerebrovasc Dis，2016，41（1/2）：87-95.
[4] DEGUCHI I，HAYASHI T，KATO Y，et al. Treatment outcomes of tissue plasminogen activator infusion for branch atheromatous disease[J/OL]. J Stroke Cerebrovasc Dis，2013，22（7）：e168-e172[2025-01-10]. https://doi.org/10.1016/j.jstrokecerebrovasdis.2012.10.012.
[5] ZI W J，SONG J X，KONG W L，et al. Tirofiban for stroke without large or medium-sized vessel occlusion[J]. N Engl J Med，2023，388（22）：2025-2036.
[6] LI X Q，HOU X W，CUI Y，et al. Safety and preliminary efficacy of argatroban plus dual antiplatelet therapy for acute mild to moderate ischemic stroke with large artery atherosclerosis[J/OL]. Brain Behav，2022，12（7）：e2664[2025-01-10]. https://doi.org/10.1002/brb3.2664.
[7] XU J H，XU X J，WANG H Z D，et al. Dual antiplatelet therapy plus argatroban prevents early neurological deterioration in branch atherosclerosis disease[J/OL]. Stroke，2022，53（1）：e19-e20[2025-01-10]. https://doi.org/10.1161/STROKEAHA.121.036356.
[8] 门雪娇，陈玮琪，许玉园，等. 穿支动脉粥样硬化病中国专家共识[J]. 中国卒中杂志，2021，16（5）：508-514.
MEN X J，CHEN W Q，XU Y Y，et al. Chinese expert consensus on the diagnosis and management of branch atheromatous disease[J]. Chin J Stroke，2021，16（5）：508-514.
[9] 王一轻，刘平国，沈佳慧，等. 脑穿支动脉病变梗死类型和神经影像学研究进展[J]. 中国卒中杂志，2021，16（9）：876-882.
WANG Y Q，LIU P G，SHEN J H，et al. Infarct types and neuroimaging progress of cerebral perforating artery disease[J]. Chin J Stroke，2021，16（9）：876-882.
[10] KWON H M，LEE Y S，BAE H J，et al. Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke[J]. Stroke，2014，45（3）：871-873.
[11] CAPLAN L R. Intracranial branch atheromatous disease：a neglected，understudied，and underused concept[J]. Neurology，1989，39（9）：1246-1250.
[12] HE L Y，XU R H，WANG J，et al. Capsular warning syndrome：clinical analysis and treatment[J/OL]. BMC Neurol，2019，19（1）：285[2025-01-10]. https://doi.org/10.1186/s12883-019-1522-0.
[13] 王璐，王健. 穿支动脉粥样硬化病患者早期神经功能恶化的研究进展[J]. 中国卒中杂志，2023，18（10）：1191-1195.
WANG L，WANG J. Advances in the study of early neurological deterioration in patients with branch atheromatous disease[J]. Chin J Stroke，2023，18（10）：1191-1195.
[14] WU C J，SUN C H，WANG L J，et al. Low-dose tirofiban treatment improves neurological deterioration outcome after intravenous thrombolysis[J]. Stroke，2019，50（12）：3481-3487.
[15] LIU B，ZHANG H，WANG R，et al. Early administration of tirofiban after urokinase-mediated intravenous thrombolysis reduces early neurological deterioration in patients with branch atheromatous disease[J/OL]. J Int Med Res，2020，48（5）：300060520926298[2025-01-10]. https://doi.org/10.1177/0300060520926298.
[16] LI W，LIN L，ZHANG M，et al. Safety and preliminary efficacy of early tirofiban treatment after alteplase in acute ischemic stroke patients[J]. Stroke，2016，47（10）：2649-2651.
[17] 中国卒中学会，中国卒中学会神经介入分会，中华预防医学会卒中预防与控制专业委员会介入学组. 替罗非班在动脉粥样硬化性脑血管疾病中的临床应用专家共识[J]. 中国卒中杂志，2019，14（10）：1034-1044.
Chinese Stroke Association，Chinese Interventional Neuroradiology Society，Intervention Group of Committee of Stroke Prevention and Control of Chinese Preventive Medicine Association. Expert consensus on clinical application of tirofiban in atherosclerotic cerebrovascular disease[J]. Chin J Stroke，2019，14（10）：1034-1044.
[18] 北京神经科学学会血管神经病学专业委员会，阿加曲班治疗急性缺血性卒中中国专家共识组. 阿加曲班治疗急性缺血性卒中中国专家共识2021[J]. 中国卒中杂志，2021，16（9）：946-953.
Vascular Neurology Committee of Beijing Society for Neuroscience，Chinese Expert Consensus Group on Argatroban Therapy in Acute Ischemic Stroke. Chinese expert consensus on argatroban for acute ischemic stroke 2021[J]. Chin J Stroke，2021，16（9）：946-953.
[19] KIMURA T，TUCKER A，SUGIMURA T，et al. Ultra-early combination antiplatelet therapy with cilostazol for the prevention of branch atheromatous disease：a multicenter prospective study[J]. Cerebrovasc Dis Extra，2016，6（3）：84-95.
[20] JUNG H J，RYU J C，JOON KIM B，et al. Time window for induced hypertension in acute small vessel occlusive stroke with early neurological deterioration[J]. Stroke，2024，55（1）：14-21.
[21] NISHI R，MANO T，KOBAYASHI Y，et al. Argatroban，aspirin，and clopidogrel combination therapy for acute penetrating artery infarction：a pilot study[J]. Brain Nerve，2016，68（2）：181-189.
[22] ZHANG X T，ZHONG W S，XUE R，et al. Argatroban in patients with acute ischemic stroke with early neurological deterioration：a randomized clinical trial[J]. JAMA Neurol，2024，81（2）：118-125.